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Abstract: Malignant melanoma is the most aggressive type of skin cancer and is closely associated 
with the development of brain metastases. Despite aggressive treatment, the prognosis has 
traditionally been poor, necessitating improved therapies. In melanoma, the mitogen activated 
protein kinase and the phosphoinositide 3-kinase signaling pathways are commonly altered, and 
therapeutically inhibiting one of the pathways often upregulates the other, leading to resistance. 
Thus, combined treatment targeting both pathways is a promising strategy to overcome this. Here, 
we studied the in vitro and in vivo effects of the PI3K inhibitor buparlisib and the MEK1/2 inhibitor 
trametinib, used either as targeted monotherapies or in combination, on patient-derived melanoma 
brain metastasis cell lines. Scratch wound and trans-well assays were carried out to assess the 
migratory capacity of the cells upon drug treatment, whereas flow cytometry, apoptosis array and 
Western blots were used to study apoptosis. Finally, an in vivo treatment experiment was carried 
out on NOD/SCID mice. We show that combined therapy was more effective than monotherapy. 
Combined treatment also more effectively increased apoptosis, and inhibited tumor growth in vivo. 
This suggests a clinical potential of combined treatment to overcome ceased treatment activity 
which is often seen after monotherapies, and strongly encourages the evaluation of the treatment 
strategy on melanoma patients with brain metastases. 
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1. Introduction 
Melanoma is the most lethal and aggressive type of skin cancer, but only represents around 5% 
of all cases of skin cancer [1]. Together with non-small cell lung cancer (non-small-cell lung cancer; 
NSCLC) and breast cancer, melanoma has the highest propensity of all cancers to induce brain 
metastases. Around 50% of melanoma patients with metastatic disease exhibit cancer spread to the 
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brain, a number that rises to more than 70% at autopsy [2]. The incidence is increasing [3], and despite 
the use of standard as well as novel therapies, metastatic melanoma is associated with divergent 
prognoses [4]. Thus, there is still an urgent need for developing new and improved treatment 
strategies for melanoma patients. 
Comprehensive surveys of the genetic landscape of malignancies have shown that melanomas 
have the highest mutation frequency of all cancers analyzed [5]. In particular, the mitogen activated 
protein kinase (MAPK) and the phosphoinositide 3-kinase (PI3K) signaling pathways are commonly 
altered in melanoma [6]. Up to 90% of melanomas display an aberrant activation of the MAPK 
pathway, leading to cell cycle deregulation and inhibition of apoptosis [7]. The most common somatic 
mutations are activating point mutations in the v-Raf murine sarcoma viral oncogene homolog 
(BRAF; 35–50% of melanomas) and neuroblastoma RAS viral oncogene homolog (NRAS; 10–25%), as 
well as loss-of-function mutations affecting neurofibromin 1 (NF1; ~15%) [8]. The substitution of 
valine for glutamic acid (V600E) is found in approximately 90% of all BRAF mutations (BRAFV600E) 
[9]. Activated BRAF leads to the down-stream activation of protein mitogen-activated protein kinase 
kinase (MEK) by inducing phosphorylation of the serine residues. Activated MEK triggers the 
serine/threonine kinase extracellular signal-regulated kinase (ERK) by phosphorylation of the Thr-
Glu-Tyr motif. The phosphorylated ERK translocates into the nucleus and regulates gene expression 
of over 50 substrates leading to progression of cancer [10]. 
The PI3K signaling pathway is also frequently activated in melanoma, often as a consequence of 
mutations or loss of phosphatase and tensin homolog (PTEN); an inhibitor of protein kinase B (Akt), 
and further dysregulation of Akt expression [11]. This pathway plays a key role in inducing drug 
resistance after treatment of melanoma patients with BRAF/MEK inhibitors, and is thus a decisive 
target for melanoma therapy [12]. More specifically, PI3K activation has been highlighted as a 
particularly important driver of metastases in the brain [13]. Furthermore, it has been shown that 
PI3K signaling may result in therapeutic resistance in BRAFV600E mutated metastatic melanoma by 
modulating MAPK signaling and altering MEK activity [14]. Inhibition of one of the pathways often 
upregulates the other, thereby inducing resistance to therapy [15]. 
Mutations in MEK can induce resistance to BRAF inhibition; however, combining a MEK 
inhibitor with a PI3K inhibitor has been found to overcome this resistance [16]. Thus, a combined 
PI3K and MEK inhibition can ensure suppression of downstream proliferation, inhibition of growth, 
and survival signals in tumors. The combination of two such inhibitors can, therefore, enhance 
toxicity. Trametinib is one of the most effective allosteric inhibitors of MEK1/MEK2 activation and 
kinase activity [17]. The U.S. Food and Drug Administration (FDA) has approved trametinib 
(GSK1120212) for treatment of BRAF-mutant metastatic melanoma [18], and a phase III clinical trial 
using trametinib in melanomas with BRAFV600E or BRAFV600K mutations showed promising responses 
[19]. Furthermore, more than 30 small molecule PI3K inhibitors have entered clinical trials [20]. A 
common disadvantage is that they may not effectively downregulate all isoforms of PI3K [21]. 
Buparlisib (BKM120) is an oral pan-class I PI3K inhibitor targeting all isoforms of PI3K [22]. The anti-
proliferative, pro-apoptotic, and antitumor activity of buparlisib has been demonstrated preclinically 
[23] and in clinical trials [24]. 
In the present study, we investigated the combinatorial effect of the targeted therapies buparlisib 
and trametinib in vitro and in vivo on patient-derived melanoma cell lines of brain metastatic origin. 
Through mechanistic investigations, we show that combined treatment using trametinib and 
buparlisib was more effective than monotherapy regarding increasing tumor cell death, which could 
indicate a way of overcoming ceased treatment effect, as is often observed in the clinic.  
2. Results 
2.1. Combined Trametinib and Buparlisib Treatment Is More Effective Than Monotherapies In Vitro 
Assessing the effects of trametinib and buparlisib monotherapies as well as the combination of 
the two, we used four different patient-derived melanoma cell lines; H1, H2, H3 and H10. All four 
were of brain metastatic origin and all four harbored BRAF mutations (H3 harbored BRAFL577F while 
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H1, H2 and H10 harbored the canonical BRAFV600E). Treating the cells with buparlisib reduced cell 
viability to a greater extent than trametinib in both H1 and H2 cells (Figure 1a,b). Combined treatment 
was more effective than either monotherapy in H1 cells, whereas combined treatment did not further 
increase cell death in H2 cells (Figure 1b, Supplementary Figure S1). The H10 cells were more 
sensitive to trametinib than buparlisib, and combined treatment was more effective than either of the 
monotherapies (Figure 1b, Supplementary Figure S1). The BRAFL577F mutated H3 cells were more 
resistant to single drug treatment than the other BRAFV600E mutated cell lines. Nevertheless, combined 
treatment was more effective than the single drug treatments (Figure 1b, Supplementary Figure S1). 
These results were used as a baseline for further in vitro experiments.  
 
Figure 1. Cell survival curves of cells grown as monolayers after treatment with buparlisib, trametinib 
or a combination with increasing drug concentrations (0.000001 μM–100 μM). (a) representative 
graphs of H1 cells treated with increasing drug concentrations for 72 h, with either buparlisib, 
trametinib, or combined treatment; (b) table showing the IC50 doses, the doses at which 50% of the 
cells were growth inhibited, for all four cell lines studied. The experiments were performed in 
triplicate (n = 6 per experiment per drug concentration). 
2.2. Treatment with Buparlisib and Trametinib Decreases Target Protein Expressions 
To validate the cellular expression of the two signaling pathways upon therapeutic inhibition, 
lysates from H1, H2, H3 and H10 were prepared for Western blot analysis. Untreated H1, H2, H3 and 
H10 cells all expressed PI3K activation and MEK1/2 phosphorylation (Figure 2a,b and 
Supplementary Figure S2). The expression of PI3K activity and MEK1/2 phosphorylation decreased 
after single monotherapies, however, combined treatment most effectively downregulated the 
protein expressions. 
 
Figure 2. Protein expression of cell lysates after in vitro treatment with 10 μM buparlisib, 10 μM 
trametinib or combination (5 μM + 5 μM). (a) Western blots of lysates from H1 cells showing the 
expression of PI3K and MEK1/2; (b) quantification of PI3K and MEK1/2 expression relative to β-actin. 
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2.3. Combined Treatment Inhibits 2D and 3D Colony Formation More Effectively Than Single Drug 
Treatment 
To study whether the therapeutic strategy inhibited cell growth after pre-treatments as an 
indication of colony formation, we carried out clonogenic assays in 2D and 3D. Out of the four cell 
lines, only H1 and H2 cells grew as colonies in 2D. Cells pre-treated with buparlisib developed 43.7% 
colonies compared to untreated cells, and H1 cells pre-treated with trametinib developed 30% 
colonies (for both, p < 0.01; Figure 3a). Combination treatment was most effective, as only 17.5% 
colonies developed, compared to untreated cells (p < 0.05 compared to trametinib treatment; Figure 
3a). For H2 cells, single drug treatment with buparlisib was more effective than trametinib, whereas 
combinatorial treatment again was more efficient than single drug treatments (p < 0.0001 compared 
to untreated cells, Supplementary Figure S3). 
 
Figure 3. In vitro colony formation of H1 cells after pre-treatment with buparlisib and trametinib. (a) 
representative images of H1 cells pre-treated with 10 μM buparlisib, 10 μM trametinib or a 
combination (5 μM buparlisib + 5 μM trametinib) grown as colonies. The colony formation was scored 
and quantified as seen in the graph to the right; (b) representative images of H1 cells pre-treated with 
corresponding drug concentrations seeded into low melting point agarose and incubated for 21 days. 
Scale bar = 50 μM. The percentage area covered by the spheroids within the total visual field was 
quantified as seen to the right. The experiments were performed in triplicate (n = 4 images). 
Abbreviations: *: p < 0.05, **: p < 0.01 and ****: p < 0.0001. 
Only H1 cells grew as colonies in a 3D anchorage-independent culture environment. H1 cells 
pre-treated with trametinib and grown in the same conditions covered in comparison around 91.0% 
of the field of view. Cells treated with buparlisib covered around 78.4% of the total area (p < 0.01, 
compared to untreated cells), while the area covered after combined treatment was around 22.1% (p 
< 0.0001, compared to untreated cells; Figure 3). 
2.4. Tumor Cell Migration and Directional Cell Migration Towards a Chemo-Attractant Is Hampered by 
Combination Treatment 
Since we observed reduced clonogenic growth after pre-treatment in monolayer and anchorage-
independent cell cultures, we studied the migratory capacity of the metastatic cells after treatment. 
Accordingly, we carried out two different migration assays: a scratch wound assay and a trans-well 
assay. 
During the scratch wound assay, the cells were under constant exposure to the respective drugs. 
The wound confluence measured during the experiments was scaled to percentage during analysis. 
Across all cell lines, the most efficient treatment was a combination of buparlisib and trametinib, 
followed by buparlisib and then trametinib (Figure 4, Supplementary Figure S4). After approximately 
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50 h, the wound was completely closed for untreated H1 cells (Figure 4a, b). After 90 h, none of the 
other treatment groups had managed to regrow the wound completely. The lowest percentage of 
confluence was observed after combined treatment of the H1 cells (Figure 4a, b). Among the other 
cell lines used, H3 was the only one that was completely regrown into the wound upon completion 
of the experiment at 90 h (Supplementary Figure S4b). H10 cells were the most sensitive to all 
treatments (Supplementary Figure S4c). 
 
Figure 4. Migration of H1 cells during and after pre-treatment with 10 μM buparlisib, 10 μM 
trametinib or a combination (5 μM buparlisib + 5 μM trametinib). (a) representative micrographs of 
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H1 cells before (0 h) and at completion (90 h) of the scratch-wound experiment. The drugs were added 
at initiation of the time-lapse experiment. Scalebar = 300 μm; (b) quantification of wound confluence 
throughout the time-lapse across the different treatment groups (n = 6 per drug concentration); (c) 
representative images of migrated H1 cells pre-treated with buparlisib, trametinib or a combination. 
Scalebar = 50 μm; (d) quantification of H1 cells allowed to migrate towards a chemo-attractant for 48 
h. The experiment was carried out in triplicate (n = 3 representative fields of view per experiment). 
Abbreviations: *: p < 0.05. 
In the trans-well assay, the evaluation of cell migration was carried out after pre-treating the 
cells with the respective drugs for 24 h. In contrast to the scratch-wound assay, the trans-well assay 
revealed that trametinib was a more effective monotherapy than buparlisib regarding inhibiting 
migratory properties of cells across all cell lines. In addition, here, the combination treatment was 
more effective than either of the monotherapies (Figure 4c,d and Supplementary Figure S5). 
2.5. Melanoma Cell Morphology Is Altered upon Combination Treatment 
The morphology of the brain metastatic melanoma cells was observed to change upon treatment 
with buparlisib and trametinib. For all four cell lines, an elongated morphology was observed after 
treatment with trametinib, whereas buparlisib or combination treatment resulted in a circular cell 
shape with reduced attachments (Supplementary Figure S6).  
2.6. Combined Treatment Induces More Apoptosis Than Single Drug Treatment 
To assess whether the altered morphology could indicate apoptosis, we studied this by flow 
cytometry using a PI and annexin V assay after treating the cells for 72 h (Figure 5). Combination 
treatment reduced cell viability across all four cell lines, by entering early or late apoptosis (Figure 
5). For untreated H1 cells, around 94% of the cells were viable (Figure 5a, b). Single drug treatment 
decreased the number of viable cells to around 55%, while combined treatment decreased the number 
of viable cells to around 40%. Approximately 10% of the H2 cells survived after trametinib treatment, 
and almost 30% of the cells were healthy after being exposed to buparlisib. Combined treatment 
resulted in a 7% cell survival (Figure 5b). For the H3 cell line, cell survival after exposure to single 
drug treatment was around 58% (trametinib) and 37% (buparlisib). In addition, here, combined 
treatment effectively reduced cell survival, compared to monotherapies to around 25% (Figure 5b). 
Between 40–50% of H10 cells treated with single drugs survived the treatment. Here, combined drug 
treatment effectively reduced the number of healthy cells to approximately 6% (Figure 5b). For H1, 
H2 and H10, trametinib was the most effective monotherapy. For H3 cells, buparlisib was the most 
effective monotherapy. 
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Figure 5. Flow cytometric analysis of apoptosis after treatment of melanoma brain metastasis cells 
with buparlisib and trametinib. (a) Representative dot plots of H1 cells treated with 10 μM buparlisib, 
10 μM trametinib or combination (5 μM buparlisib and 5 μM trametinib). Annexin V labels apoptotic 
cells, while Propidium Iodide labels necrotic cells. (b) Quantification of the percentage of viable, 
apoptotic and necrotic cells for the H1, H2, H3 and H10 cell lines. The experiments were done in 
triplicate (n = 3 per experiment per drug concentration). Abbreviations: Q1: viable cells, Q2: cells in 
early apoptosis, Q3: late apoptotic cells, Q4: necrotic cells, ns: not significant, *: P < 0.05 and ****: P < 
0.0001. 
To gain a more detailed, mechanistic understanding of the observed apoptosis, we conducted 
an apoptosis array experiment (Figure 6a, b). Both monotherapy and combination treatment resulted 
in statistically significant increases in expressions of the apoptotic proteins Bad, cleaved caspase-3, 
p27/kip1 and tumor necrosis factor receptor 1 (TNFR1). There were also tendencies of increased 
expression of cytochrome-C, TRAIL R2 and Fas in the monotherapies (Figure 6a). Expression of key 
inhibitors of apoptosis such as Bcl-2, cIAP-1, claspin, HIF-1α, HSP70, survivin and XIAP were 
significantly downregulated by both the monotherapies and the combination treatment. Tendencies 
of decreased expression after monotherapies were also seen in HSP27 (Figure 6b). 
 
Figure 6. Expression of apoptosis associated proteins after treatment of H1 cells with 10 μM 
buparlisib, 25 nM trametinib or a combination (5 μM buparlisib + 12.5 nM trametinib). (A) graphic 
presentation of results from the apoptosis array, showing expression of key molecules involved in 
apoptosis in H1 cells treated with 20 μM buparlisib, 50 nM trametinib, or 10 μM buparlisib + 25 nM 
trametinib, for 72 h; (B) graphic representation of key molecules involved in anti-apoptotic activity in 
H1 cells after buparlisib and trametinib treatment; (C) Western blots showing the expression of 
selected apoptotic and anti-apoptotic proteins in addition to PARP; (D) quantification of Western blot 
results relative to β-actin. Abbreviations: Clv cas-3: cleaved caspase-3, cyt C: cytochrome C, full: full 
length PARP, clv: cleaved, *: p < 0.05, **: p < 0.01, ***: p < 0.001 and ****: p < 0.0001. 
A selection of key apoptotic and anti-apoptotic proteins identified from the apoptosis array 
(Figure 6a and b) was then verified by quantitative Western blot analyses (Figure 6c,d). Statistically 
significant increases in protein levels of cleaved caspase-3 were found for lysates from H1 cells treated 
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with trametinib (p < 0.01). Increased expression of p27/kip1 was seen for cells treated with trametinib 
and combination therapy (both p < 0.0001). Statistically significant decreases were also detected for 
Bcl-2 in the combination group (p < 0.05) and for HIF-1α across buparlisib, trametinib and 
combination group (p < 0.001, 0.0001 and 0.0001, respectively). PARP, which is considered a hallmark 
of apoptosis, was also downregulated in the combination group (p < 0.05; Figure 6c and d). 
2.7. The Combinatorial Approach Is More Efficacious Than Single Treatments in Vivo 
The finding that combined treatment with buparlisib and trametinib in vitro was more efficient 
than single treatments was validated in vivo in NOD/SCID mice with subcutaneous H1_DL2 derived 
tumors. At the endpoint of the experiment (after 30 days), the average tumor volume in the 
combination group was 37.7 mm3, in the trametinib group 89.7 mm3, in the buparlisib 186.3 mm3 and 
the tumors in the vehicle group 746.7 mm3 (Figure 7a). Compared to vehicle treated tumors, 
buparlisib, trametinib and combination treated mice showed a statistically significant reduction in 
total tumor volumes (all p < 0.0001). When the combination treatment group was compared to the 
trametinib group, there was also a statistically significant difference (p < 0.01; Figure 7a).  
 
Figure 7. Inhibition of in vivo tumor growth after treatment with 50 mg/kg buparlisib and 1 mg/kg 
trametinib. (a) tumor volumes plotted as a function of time to assess tumor growth in response to 
therapy. The tumors were measured once a week and at the end-point of the experiment (30 days). 
Representative images of subcutaneous tumors after termination of the experiment can be seen on the 
right (n = 8 mice in each treatment group); (b) immunohistochemistry sections from representative 
mice from each treatment group stained with antibodies against Ki67 (imaged with a 10× objective); 
(c) quantification of the number of Ki67 positive cells in each treatment group. Abbreviations: **: p < 
0.01 and ****: p < 0.0001. 
The number of Ki67 positive cells was quantified from histological sections from tumor tissue 
across all treatment groups. There were statistically significant differences between vehicle treated 
tumors and all treatment groups (all p < 0.0001; Figure 7b and c). 
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3. Discussion 
In view of previous research showing a synergic effect of combining MEK1/2 and PI3K inhibitors 
[25], we evaluated the therapeutic activity of the combinatorial approach in BRAFV600E and BRAFL577F 
mutated melanoma cells of brain metastatic origin. Although combined treatment with buparlisib 
and trametinib have been carried out previously for a variety of cancers [26–29], the combined use of 
these two drugs for treatment of brain metastatic melanoma has not been investigated to date. Thus, 
our results should encourage further studies to develop this to be a novel treatment strategy for 
patients with melanoma brain metastasis. 
MAPK inhibition has previously been associated with acquired treatment resistance [18]. The 
PI3K pathway represents a second essential signaling pathway in melanoma progression, as brain 
metastasis are often PI3K activated [12,13]. It has previously been shown that activation of the PI3K 
pathway can mediate resistance to MEK inhibitors [30]. In addition, inhibition of the PI3K pathway 
can sensitize melanoma cells towards chemotherapies [31]. PI3K inhibition using buparlisib has 
previously been demonstrated as a promising treatment strategy in BRAF mutated brain metastases 
in nude mice [32]. In a phase Ib clinical trial treating cancer patients (nine of the patients had 
cutaneous melanoma) with buparlisib and trametinib, the treatment was shown to be well tolerated 
in the short term [29]. 
In our experiments, trametinib downregulated the expression of MEK1/2 in all BRAFV600E cell 
lines. In the BRAFL577F mutated cell line H3, there was no reduction in protein expression, which may 
indicate resistance against trametinib. Upon treatment with buparlisib, however, PI3K was 
downregulated in all cell lines, and the combinatorial approach reduced the protein expression in all 
cell lines, regardless of BRAF status. Our results suggest that cell lines not harboring the BRAFV600E 
mutation may be more susceptible to PI3K inhibition. This is in line with previous research, where a 
decrease in Akt phosphorylation and hence buparlisib activity in both BRAFWT and BRAFV600E 
mutated melanoma cells was demonstrated [32]. Our results also indicate a higher degree of 
resistance towards MEK inhibition and that adding PI3K inhibitors has the potential to abrogate 
trametinib resistance. We emphasize that the mutation found in the H3 cells has not been reported in 
the literature to date, so the oncogenic potential of this mutation is not clear. 
Of the cell lines used in this study, only H1 and H2 cells were able to grow as monolayer colonies 
when pre-treated and thereafter seeded in 6-well plates. For both cell lines, there was a statistically 
significant difference in growth between untreated and combination treated cells (both p < 0.0001). 
For the H1 cells, the most efficient drug was trametinib, whereas buparlisib inhibited cell growth 
more in H2 cells. When grown in an anchorage-independent environment, the effects of the 
monotherapies were greatly reduced, as compared to the monolayer experiments. This is likely 
explained by the more realistic representation of the in vivo situation in 3D [33]. 
It has formerly been reported that buparlisib can alter the cell morphology by means of reduced 
focal adhesion and changes in the microtubule dynamics [27]. In our study, all cell lines exhibited 
traits that could be consistent with the onset of apoptosis after buparlisib treatment, which was also 
seen after combined treatment. We also observed a different morphology in cells treated with 
trametinib; however, this change resembled an epithelial-mesenchymal transition (EMT), which is 
associated with loss of apicobasal polarity and stable cell-cell adhesion. This has also been reported 
previously after treatment with MAPK inhibitors of melanoma cells [28] and NSCLC cells [26]. Our 
flow cytometry experiments showed that, for all BRAFV600E mutated cell lines (H1, H2 and H10), 
trametinib induced more apoptosis than buparlisib, and combination treatment further enhanced the 
effect. In addition, here, H3 was more resistant to trametinib and more susceptive to PI3K inhibition.  
As mentioned initially, melanoma has a strong tendency to metastasize to the brain. It is 
acknowledged that metastasis is a dynamic process dependent on the ability of tumor cells to migrate 
in the microenvironment [34]. Scratch wound assays evaluate the ability of cells to migrate and close 
an induced wound when grown as a monolayer, whereas trans-well assays give information on the 
propensity of cells to detect and subsequently migrate towards a chemo-attractant through a physical 
barrier [35]. During constant exposure to the drugs in the scratch wound assay, buparlisib inhibited 
cell migration more than trametinib. Interestingly, it has previously been shown that a MEK inhibitor 
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was able to promote cell migration, despite drug-induced cell death in a dose-dependent manner 
[36]. Concerning the trans-well assay, measuring cell migration towards a chemoattractant, pre-
treating cells with trametinib seemed to inhibit cell migration more than buparlisib. This may indicate 
that trametinib exhibits a longer lasting anti-tumor effect compared to buparlisib in vitro. It could 
also suggest that melanoma cells are less likely drawn towards a chemoattractant after inhibition of 
the MAPK compared to the PI3K signaling pathway. In both experimental layouts, combined 
treatment was the most effective across all cell lines.  
Combined treatment upregulated the expression of the four apoptotic markers bad, cleaved 
caspase 3, p27/kip1 and TNFR1. The results for cleaved caspase 3 and p27/kip1 were verified by 
Western blots. Bad is a member of the Bcl-2 family, a substrate of Akt and represents a converging 
link between inhibition and promotion of apoptosis [37]. Caspase 3 is known as the master regulator 
of apoptosis and has interestingly been shown to regulate the repopulation of tumors after apoptosis 
has occurred following treatment [38]. Across all groups, we found a substantial increase in the levels 
of the cyclin-dependent kinase inhibitor p27/kip1, whose inhibition is characteristic for malignant 
growth and PI3K inhibition is linked to p27/kip1 inactivation [39]. The tumor necrosis factor receptor 
(TNFR) is activated by cytokines belonging to the TNF protein family. Upon receptor mediated 
activation, apoptosis might be induced. Therapeutic MAPK inhibition is associated with acquired 
drug resistance [40], which may be mediated through increased PI3K signaling [12]. The PI3K 
signaling pathway regulates the expression of anti-apoptotic proteins such as Bcl-2[41], cIAP-1[42], 
claspin [43], HIF-1α [44], Hsp27 [45], Hsp70 [46], XIAP [47] and surviving [48]. In general, we also 
found reduced expression levels in the anti-apoptotic proteins after treatment. Expression levels of 
Bcl-2, cIAP-1 and HIF-1α were verified by Western blots. For all three markers, combinatorial 
treatment resulted in statistically significant reductions in protein levels. Reduced levels of Bcl-2 
subsequent trametinib and combination treatment is in line with previous research [49]. Furthermore, 
high tumor levels of HIF-1α have been associated with apoptosis and higher survival rates [50]. HIF-
1α is also known to mediate the expression of vascular endothelial growth factor (VEGF) and 
promote aggressive tumor growth [44]. cIAP-1, XIAP and survivin are all members of the inhibitor 
of apoptosis (IAP) protein family [51]. Survivin expression is linked to several aberrant activations 
associated with cancer growth, such as, for instance, the PI3K and MAPK signaling pathways [48]. 
Finally, PARP cleavage is also a well-known hallmark of apoptosis [52]. Our results by Western blot 
indicated cleaved PARP in all groups; however, the difference was only statistically significant in 
buparlisib treated cells.  
In the present work, subcutaneous melanoma tumors derived from brain metastases in 
NOD/SCID mice were effectively treated with buparlisib combined with trametinib. In general, 
MEK1/2 inhibitors are well tolerated in preclinical doses up to 1030– mg/kg [53]. Trametinib doses 
around 1 mg/kg have been frequently used in vivo [54]. In our in vivo experiments, we used 1 mg/kg, 
which significantly reduced the tumor burden in the monotherapy group receiving trametinib. 
Furthermore, buparlisib has been administered daily from 2 to 50 mg/kg preclinically [27,55]. Based 
on previous reports, we chose to use 50 mg/kg in the single drug group, which was tolerated well in 
vivo. Drawn from our animal experiments, monotherapy with trametinib seemed to be more efficient 
than buparlisib on H1_DL2 tumors. This is in contrast to some of the in vitro experiments with H1 
cells; however, some of these exhibited a constant drug exposure to the tumor cells, while, in the 
preclinical study, the drugs were administered once per day, enabling time for drug clearance 
between treatments [56]. Thus, the results suggest that a constant exposure to trametinib is needed 
for optimal effect of the drug.  
Despite using a subcutaneous tumor model, our results can serve as a proof-of-principle for 
brain metastatic melanoma as well. In case of a brain metastasis model, buparlisib is expected to cross 
an intact blood-brain barrier (BBB) [27]. However, a technique for delivering trametinib across the 
BBB would have to be employed, as the relatively large molecular weight (615.39 Da) and the 
presence of efflux pumps at the site of the BBB discourages its ability to enter the brain [57]. Thus, we 
used a subcutaneous model as proof-of-principle to ensure combined drug uptake upon oral 
administration. It should, however, be noted that, in a clinical setting, the BBB is normally disrupted 
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in brain metastases larger than 2–3 mm [58], which should facilitate penetrance of trametinib into the 
brain metastatic lesions.  
4. Materials and Methods  
4.1. Cell Lines and Cell Culture 
Written consent was obtained from the patients before tumor material was collected and 
subsequently used to prepare cell lines. The Regional Ethical Committee (REC Number 013.09, 
approved 21.04.2013) and the Norwegian Directorate of Health (NSD Number 9634, approved 
25.03.2009) approved the tissue collection and biobank storage of tumor biopsies and derived cell 
lines. Cell line authentication was verified by short tandem repeat (STR) fingerprinting. 
The H1, H2, H3 and H10 cell lines were established in our laboratory from patient biopsies of 
human melanoma brain metastases. The BRAF mutation status of the H1, H2, H3 and H10 cell lines 
was investigated by performing massive parallel sequencing of the tumor DNA, according to 
published protocols [59]. The H1, H2 and H10 cell lines are V600E mutated, while the H3 cells are 
L577F mutated.  
The H1 cells were transduced with two lentiviral vectors, encoding Dendra (a green fluorescent 
protein (GFP) variant) and luciferase to obtain the H1_DL2 cell line. Flow cytometric isolation of cells 
by GFP expression was performed (BD FACS Aria, Becton Dickinson, Franklin Lakes, NJ, USA). 
All cells were grown in Dulbecco’s modified eagles medium (DMEM; Sigma-Aldrich Inc., St. 
Louis, MO, USA), supplemented with 10% heat-inactivated new-born calf serum (Thermo Fischer 
Scientific, Waltham, MA, USA), 5 μg/mL Plasmocin (Invivogen, Toulouse, France), 2% L-glutamine 
(BioWhittaker, Verviers, Belgium), penicillin (100 IU/mL) and streptomycin (100 μL/mL) 
(BioWhittaker). The cells were cultured in a standard tissue incubator at 37 °C, 100% humidity and 
5% CO₂, and trypsinated once they attained 75% confluency using 0.25% Trypsin/EDTA 
(BioWhittaker). 
4.2. Drugs 
Buparlisib (BKM-120) and trametinib (GSK1120212) were purchased from ChemieTek 
(Indianapolis, IN, USA). Both drugs were dissolved in dimethylsulfoxide (DMSO) and stock 
concentrations of 100 mM buparlisib and 80 mM trametinib were stored at −20 °C in aliquots until 
further use. 
4.3. Animals  
Female non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice were 
purchased from Envigo (Gannat, France). The animals were bred and maintained in our animal 
facility certified by the Association for Assessment and Accreditation of Laboratory Animal Care 
International. They were fed a standard pellet diet and provided water ad libitum. The National 
Animal Research Authority approved all animal procedures (application #11655, approved 
07.03.2017).  
Anesthesia was induced with 3% sevoflurane (Abbott Laboratories Ltd., Berkshire, UK) in 
oxygen and maintained with 1.5% sevoflurane in oxygen during the injection procedures. 
4.4. Cell Viability Assay  
Cell proliferation upon treatment with buparlisib and/or trametinib was studied using a 
resazurin assay, as previously described [6]. All cell lines were seeded at a density of 5 × 103 cells/well 
in 200 μL culture medium in 96 well plates (Nunc, Roskilde, Denmark) and treated with buparlisib 
or trametinib (0, 0.000001, 0.00001, 0.0001, 0.001, 0.01, 0.1, 1, 10 and 100 μM), or a combination of both 
these treatments for a period of 72 h. After treatment, 20 μl of 0.01 mg/mL resazurin (Sigma-Aldrich 
Inc., St. Louis, MO, USA) diluted in phosphate buffered saline (PBS) was added to each well and 
incubated for 4 h at 37 °C. The absorbance was measured at dual mode 560/590 using a scanning 
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multi-well spectrophotometer (Victor 3 1420 multi-label counter, Perkin Elmer, Waltham, MA, USA). 
Each treatment was performed in triplicate (n = 6 per experiment per drug concentration). IC50 
concentrations were drawn from the results, i.e., the drug concentration at which 50% of the cell 
growth was inhibited.  
4.5. Clonogenic Assays 
In order to measure the potential loss of reproductive integrity of cancer cells, clonogenic assays 
were performed. The cell lines H1, H2, H3 and H10 were seeded at a density of 5 × 10 6 cells/well in 
2 mL culture medium in 6-well plates (Nunc) and allowed to reach 75% confluency. The cells were 
then treated with 20 μM buparlisib, 50 nM trametinib or combined therapy (10 μM buparlisib and 25 
nM trametinib) for 72 h. The drug concentrations were optimized for this experiment. Untreated cells 
were maintained as controls. After treatment, the cells were washed with PBS and trypsinated using 
0.25% Trypsin/EDTA. The cells were centrifuged at 900 rpm for 4 min, the supernatant was discarded 
and the cells were resuspended in fresh culture medium. The cells were then counted using a 
Countess® automated cell counter (Invitrogen, Carlsbad, CA, USA) according to the manufacturers 
protocol. 1000 cells from each treatment were seeded in fresh 6 well culture dishes (Nunc) in 2 mL 
culture medium and allowed to grow for 12 days. After 12 days, the culture medium was removed 
from the wells and the cell layer was washed with cold PBS. The cells were thereafter fixed with 
prechilled methanol at -20°C for a period of 10 min. The methanol was removed and plates were left 
to dry. The cells were then stained using 0.5% crystal violet in 25% methanol in water for 10 min. The 
stain was removed, the cells were washed three times with milliQ water and the plate was allowed 
to dry. Colonies consisting of more than 50 cells were counted as surviving colonies. The number of 
untreated colonies were scaled to 100%. The experiment was performed in duplicate (n = 3 per 
experiment per treatment group). 
The cells were also grown in an anchorage-independent environment, using a 3D colony 
formation assay. 7.5 × 10 5 cells were seeded in T75 culture flasks (Nunc) and incubated until 
approximately 60% confluency. The culture medium was then replaced with either fresh culture 
medium (negative control), fresh culture medium containing 10 μM buparlisib, 10 μM trametinib or 
a combination of 5 μM buparlisib and 5 μM trametinib. After 72 h of incubation, the cells were 
washed with PBS, trypsinated and centrifuged (900 rpm for 4 min). The cell number was adjusted to 
a density of 8 × 10 4 cells/mL and mixed 1:1 with 0.6% low melting point agarose (Sigma-Aldrich). 
The cells were then seeded on top of 100 μL of cooled 0.6% Difco noble agar (BD Biosciences) in a 96-
well plate (Nunc) and kept at 4 °C for 20 min. The low melting point agarose layer with cells was 
then overlaid with 100 μL of fresh culture medium, and the plate was incubated for 21 days. Colony 
formation was analyzed as growth area covered by untreated H1 cells after 21 days and scaled to 
100% using micrographs taken with a Nikon TE2000 inverted microscope (Nikon Instruments Inc., 
Melville, NY, USA). The analysis was carried out using GraphPad Prism v7 (GraphPad Software Inc., 
San Diego, CA, USA). The experiment was performed in duplicate (n = 3 per experiment per drug 
treatment group). 
4.6. Cell Migration  
To study the effects of treatment on cell motility, two cell migration experiments were carried 
out. In the first experiment, H1, H2, H3 and H10 cells were plated at a density of 5 × 10 5 cells/well in 
2 mL culture medium in 6-well plates (Nunc). After 24 h, the cells were pre-treated with 10 μM 
buparlisib, 10 μM trametinib or combined therapy (5 μM buparlisib and 5 μM trametinib) for 24 h. 
An untreated well was maintained as a negative control. After incubation with drugs, the cells were 
washed twice with PBS, trypsinated and seeded at a density of 1 × 10 3 cells/well in ThinsertTM cell 
culture inserts (Greiner Bio-One GmbH, Frickenhausen, Germany) in 24-well plates (Nunc). The 
lower chambers were filled with 500 μL culture medium containing 30% serum as chemoattractant. 
After incubation in 48 h, the inserts were removed from the wells and washed with PBS to remove 
unbound cells. The inserts were fixed with 4% formaldehyde for 10 min followed by two times 
washing with PBS and staining with 0.1% crystal violet for 5 min. The inserts were then viewed using 
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a Nikon TE2000 inverted microscope, using the 1× objective for observing the migratory capacity of 
the cells. The experiment was performed in triplicate. The cells were counted from each insert in all 
treatments to obtain the migration potential. 
In the second experiment, the migratory capacity of cells was studied under constant exposure 
to drugs for 72 h. H1, H2, H3 and H10 cells were seeded at a density of 3.5 × 10 4 cells/well in Essen 
BioScience ImageLock 96-well plates (cat. no. 4379, Essen BioScience Ltd., Hertfordshire, UK). After 
24 h, a wound-maker tool was employed to simultaneously create a consistent wound with a uniform 
width across all wells. All wells were then carefully washed with preheated culture medium before 
drug solutions were added to the wells: 10 μM buparlisib, 10 μM trametinib or combined treatment 
(5 μM buparlisib and 5 μM trametinib; n = 6 per treatment group). Imaging was carried out every 2 
h using a 10× objective in the IncuCyte® Live Cell Imaging System (Essen BioScience Ltd.) and 
analysed to find the wound width in μm using the IncuCyte® Scratch Wound Cell Migration Software 
Module (cat. no. 9600-0012, Essen BioScience Ltd.). 
4.7. Apoptosis Assay  
An Annexin-V flow cytometry assay was performed to assess the effects of combination 
treatment on apoptosis. The H1, H2, H3 and H10 lines were seeded at a density of 1 × 10 5 cells/well 
in 2 mL culture medium in 6-well plates (Nunc) and allowed to reach 75% confluency. The cells were 
then treated with 10 μM buparlisib, 10 μM trametinib or combined therapy (5 μM buparlisib and 5 
μM trametinib) for 72 h. The culture medium was then removed, the cells were washed with PBS, 
trypsinated using 0.25% Trypsin/EDTA, collected and centrifuged (900 rpm for 4 min). Untreated 
cells were maintained as controls. The supernatant was discarded, and 100 μL of Annexin V binding 
buffer containing 2 μl of Annexin V and propidium iodide (PI; AlexaFluor®488 Annexin v/dead cell 
apoptosis kit; Molecular Probes, Life Technologies, Waltham, MA, USA) was added to the cells and 
incubated for 20 min in the dark. The cells were placed on ice and further analysed using a flow 
cytometer (BD Fortessa, BD Bioscience, San Jose, CA, USA). Fluorescence in the FITC-A and PE-A 
channels were gated to a two-parameter histogram, and analysed using FloJo software (Tree Star Inc., 
Ashland, OR, USA). The experiment was repeated three times (n = 3 per experiment per treatment 
group).  
4.8. Apoptosis Array 
A human apoptosis antibody array kit (R&D Systems, Inc., Minneapolis, MN, USA) was used to 
study the effects of treatment on 35 apoptosis-related proteins on H1 cells after 72 h. 1 × 10 6 H1 cells 
were plated in 2 mL culture medium in 6-well plates (Nunc), and after reaching confluency, the cells 
were treated with 20 μM buparlisib, 50 nM trametinib or combined therapy (10 μM buparlisib and 
25 nM trametinib) for 72 h, drug concentrations optimized for this specific experiment. Untreated 
wells were maintained as control. After treatment, the cells were washed and lysed using lysis buffer 
17 (R&D Systems, Inc.), and a protease inhibitor was added to the lysates to prevent them from 
degradation. The assay was performed according to the protocol provided by the manufacturer. The 
arrays were developed using chemi-reagent mix (HRP substrates) provided in the kit and viewed 
using a ChemidocTM XRS + System (Bio-Rad laboratories AB, Oslo, Norway). The band density was 
analyzed using ImageJ freeware version 2.0.0-rc-68/1.52g (National Institute of Health, Bethesda, MA, 
USA), and graphs were plotted showing the relative intensity of band density (pixels) of the various 
proteins. The experiment was performed once, and each of the 35 proteins was spotted twice on the 
membrane. 
4.9. Western Blot Analysis 
Cell lysates from H1, H2, H3 and H10 cells treated with buparlisib and/or trametinib for 72 h 
were prepared for Western blot analysis. H1, H2, H3 and H10 cells were seeded as monolayers at 40–
50% confluency one day prior to treatment, and then treated for 72 h with 10 μM buparlisib, 10 μM 
trametinib, or a combination of 5 μM buparlisib and 5 μM trametinib. Control cells were left 
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untreated. The cells were harvested, lysed in radioimmunoassay precipitation (RIPA) buffer, and 
subjected to Western blotting as described previously [6]. For protein detection, the following 
primary antibodies were used: anti-cleaved caspase-3 (rabbit monoclonal, Cell Signaling Technology, 
Danvers, MA, USA, cat. #9664, 1:1000), anti-p27 Kip1 (rabbit monoclonal, Cell Signaling Technology, 
cat #3686, 1:1000), anti-PARP (rabbit polyclonal, Cell Signaling Technology, cat. #9542, 1:1000), anti-
Bcl-2 (mouse monoclonal, NeoMarkers Fremont, CA, USA, MS-123-R1, 1:500), anti-c-IAP1 (mouse 
monoclonal, Santa Cruz Biotechnology, Inc., Dallas, TX, USA, sc271419, 1:100), anti-HIF-1α (mouse 
monoclonal, Santa Cruz Biotechnology, Inc., sc13515, 1:200), anti-PI 3-kinase p101 (rabbit polyclonal, 
Santa Cruz Biotechnology, Inc., sc390916, 1:200), anti-MEK1/2 (rabbit monoclonal, Cell Signaling 
Technology, cat. #8727, 1:1000), and anti-beta actin (rabbit polyclonal, Abcam, Cambridge, UK, 
ab8227, 1:2000). Quantification of protein bands was performed using ImageJ freeware version 2.0.0-
rc-68/1.52g. Relative protein levels were first normalized against the loading control (beta actin) and 
then calculated and presented as a ratio of the untreated control. All antibodies were studied by 
Western blots in triplicate. 
4.10. In Vivo Experiments 
In addition, 1 × 10 6 H1_DL2 cells in 0.1 mL PBS was injected subcutaneously in the neck region 
of 32 female NOD/SCID mice. After two weeks, the average tumor volume was measured to 
approximately 70 mm3. The mice were then randomized by simple randomization to daily gavage 
treatments of 0.1 mL vehicle (0.5% methyl cellulose with 0.2% Tween20), 50 mg/kg buparlisib, 1 
mg/kg trametinib, or a combination of the two latter (25 mg/kg buparlisib + 0.5 mg/kg trametinib; n 
= 8 mice in each group). The mice were monitored daily, and caliper tumor measurements were 
carried out every third day. Tumor volumes were calculated using the formula [width2×length]/2. 
The experiment was terminated after 30 days. 
4.11. Histology and Immunohistochemistry 
Paraffin-embedded tumor samples were sectioned (4 μm) and mounted on microscopic slides. 
Heat-induced epitope retrieval was performed in 10 mmol/L citric acid buffer at pH 7.2 preheated in 
a microwave and the sections were heated at 98 °C for 20 min. Sections were incubated with the 
primary antibody Ki67 (DAKO M7240, clone MIB-1, 1:250) at 4 °C overnight, rinsed with TBST, and 
incubated for 1 h at room temperature with biotin-conjugated secondary antibody, followed by 30 
min incubation with ABC complex (VECTASTAIN® ABC Kit, Vector Laboratories, Burlingame, CA, 
USA). Visualization was achieved using DAB chromogen (DAKO K3468) as the substrate, and slides 
were counterstained with haematoxylin (CellPath Ltd., Newtown, UK) and mounted with Entellan® 
new (Merck Millipore, Burlington, MA, USA, 107961). Images were obtained using a Nikon TE2000 
inverted microscope (Nikon Instruments Inc., Melville, NY, USA), and the percentages of Ki-67 
positive cells were calculated, counting positive and negative cells using the point tool in the ImageJ 
freeware. 
4.12. Statistical Analysis 
The cell migration in trans-well layout was compared using Dunnett’s multiple comparisons test 
and the flow data was analyzed using a two-way ANOVA test with Tukey’s multiple comparisons 
test. The values from the apoptosis array were scaled to fold-change and compared using unpaired 
t-tests with Holm–Sidak’s correction. For the in vivo treatment experiment, the differences in 
endpoint tumor volumes were compared using the Mann–Whitney test. All other comparisons were 
carried out using unpaired, two-tailed t-tests. All statistical analyses were carried out using 
GraphPad Prism v7 (GraphPad Software, Inc.). Values presented in the figures represent means ± 
standard error mean (SEM). A two-tailed p ≤ 0.05 was considered to be statistically significant. 
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5. Conclusions 
In conclusion, we show that the combined treatment with buparlisib and trametinib was 
superior to monotherapies in vitro, inhibiting growth and migration and inducing apoptosis in 
human melanoma brain metastasis cells. In our proof-of-principle in vivo study, the combinatorial 
approach was also more effective than monotherapies. Thus, with the improved mechanistic 
understanding of the treatment activity of combining buparlisib and trametinib presented here, our 
findings strongly encourage further evaluation of the novel combinatorial treatment approach on 
brain metastatic melanoma. 
Supplementary Materials: Supplementary Figure S1: Cell survival curves with indicated IC50 concentrations of 
cells grown as monolayers after treatment with buparlisib, trametinib or combination. Supplementary Figure 
S2: Protein expression of cell lysates after in vitro treatment with 10 μM buparlisib, 10 μM trametinib or 
combination (5 μM + 5 μM). Supplementary Figure S3: In vitro colony formation of H2 cells pre-treated with 
buparlisib and trametinib. Supplementary Figure S4: Migration of brain metastatic melanoma cells during and 
after pre-treatment with 10 μM buparlisib, 10 μM trametinib or combination (5 μM + 5 μM). Supplementary 
Figure S5: Cell migration towards a chemoattractant. Supplementary Figure S6: Morphology of human 
melanoma brain metastatic cell lines after treatment with 10 μM buparlisib, 10 μM trametinib or combination (5 
μM + 5 μM).  
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